Physiologically Based Pharmacokinetics

(M-003) Determining an Appropriate Fosfomycin Dosing Regimen in Pneumonia Patients by Utilizing minimal PBPK Modeling and Target Attainment Analysis

(M-029) Bilirubin Elevation Due To Atazanavir Treatment May Primarily Be Mediated By Inhibition Of OATP1B1/3 Rather Than That Of UGT1A1: PBPK Analysis Of Bilirubin-Atazanavir-Polymorphism Interaction

(M-032) A Whole-body Mechanistic Physiologically-based Pharmacokinetic Modeling of Intravenous Iron

(M-039) A PBPK-QSP model for regulation of thyroid hormones in Allan-Herndon Dudley Syndrome

(M-046) Development and Application of Inavolisib Physiologically-based Pharmacokinetic (PBPK) Model for Drug-drug Interaction (DDI) Assessment

(M-059) Physiologically based pharmacokinetic (PBPK) modeling of methotrexate in cerebrospinal fluid in humans

(M-080) Development of a Simeprevir PBPK Model to Describe Changes in Coproporphyrin-I, an Endogenous OATP1B Biomarker, in Subjects with HCV

(M-081) Population Pharmacokinetic and Exposure-Response Analyses of Valbenazine in Patients with Huntington’s Disease Chorea

(M-089) A minimal PBPK model to study the effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody PK

(M-107) Physiologically-Based Pharmacokinetic Modeling of Maribavir Incorporating Metabolism by Cytochrome P450, Glucuronidation, and Hepatic Uptake, for Prediction of Victim Drug-Drug Interaction Potentials

(M-125) Explore the Impact of Pharmacological Target-Mediated Low Plasma Exposure in Lead Compound Selection in Drug Discovery – a Modeling Approach

(M-129) Automating Translational Physiologically Based Pharmacokinetic Modeling with R and Simcyp: An Innovative Approach

(M-130) Across-species meta-analysis of methylprednisolone reversible metabolism and pharmacokinetics utilizing allometric and scaling model approaches

(M-131) Physiologically based pharmacokinetic modeling the reversible metabolism and tissue-specific partitioning of methylprednisolone and methylprednisone in rats

(M-134) A Minimal Physiology-based Pharmacokinetics Model of Blood-Brain Barrier Transport for Monoclonal Antibodies Targeting the Transferrin Receptor

(T-001) A Model-based Pharmacokinetic Simulation Tool to Aid Dose Selection of Antisense Oligonucleotides Administered Intrathecally in Pediatrics

(T-006) Inhibitory Potential of Cannabidiol on Major CYP450s Enzymes: Insights from Physiological-based Pharmacokinetic Modeling

(T-017) Application of an advanced gut PBPK model to characterize intestinal transport and P-glycoprotein-mediated drug-drug interaction: a case study with Digoxin and Clarithromycin

(T-021) Semi-physiological population pharmacokinetic (PPK) model using dose optimization data for ASTX030, an oral fixed-dose combination (FDC) of CDA inhibitor cedazuridine and azacitidine in MDS patients

(T-025) Meta-Analysis of Levamisole Pharmacokinetics Across Diverse Species

(T-027) Integrated Microphysiological System and PBPK Modeling for Prediction of Human Diclofenac Pharmacokinetics

(T-032) NMsim: Simulate Nonmem models seamlessly in R without any model reimplementation

(T-033) A translational one pore and two pore whole body physiologically based pharmacokinetic model for ASOs, and siRNA-based therapeutics

(T-038) The PK-PD model of dexamethasone for fetal lung maturation and developmental neurotoxicity: A dose optimization study

(T-039) Symbolic PBPK-PDE Modeling Using Open-Source Julia Tools

(T-050) A review of OSP suite PBBM capabilities: looking ahead

(T-068) An integrated model of catabolic clearance mechanisms driving exposure-response confounding for immunotherapies in cancer: interactions between mAb drugs, Fc receptors, and endogenous serum proteins

(T-082) Optimizing Clinical Dosing Strategies to Mitigate Corneal Toxicity: Ocular PBPK Model-Based Evaluation of the Extent and Rate of Therapeutic Protein Distribution in the Human Cornea

(T-084) A COMBINED EX VIVO AND PHYSIOLOGICALLY-BASED PHARMACOKINETIC APPROACH TO INCORPORATE DRUG-DRUG INTERACTIONS FOR DOSING DURING CONTINUOUS RENAL REPLACEMENT THERAPY

(T-086) Development of a Whole-Body Physiologically Based Pharmacokinetics (PBPK) Model for Predicting Dynamics of mRNA and Protein for LNP-Encapsulated mRNA Therapeutics

(T-090) Whole-body Two-pore PBPK Model to Investigate the Disposition of Immunoglobulin M (IgM) in Mice

(T-102) Redefining Multidrug Resistance Quantitatively using Live Cell Functional Data

(T-130) Development of the second-generation PBPK model to quantify OATP1B, P-gp, BCRP transporter and CYP3A4 enzyme activity changes for Chinese ESRD patients

(T-134) Integrating Physiologically Based Pharmacokinetic (PBPK) Modeling and Strain-Specific Exposure-Efficacy Requirements to Refine the Dosage Regimens for Voriconazole in a Pediatric Cancer Population

(T-136) Unique Effect of the High-Fat Meal on the Pharmacokinetics of Omaveloxolone Explained by Physiologically Based Biopharmaceutics Modeling

(T-137) Mechanistic physiologically-based pharmacokinetic platform model to characterize risk of cytochrome P450 based drug-drug interactions for bispecific T cell engagers in oncology patients

(W-002) Dual Physiologically-based Pharmacokinetics Models of Nano-Liposomal (Nal-IRI) and Non-Liposomal Irinotecan in Ewing’s Family Tumor Xenograft

(W-005) Utilizing PBPK/RO model for description of GEN1042 (BNT312) PK and prediction of trimer level to guide dose selection

(W-009) A Physiological-Based Pharmacokinetic (PBPK) Model embedded with Pulmonary Compartmental Absorption and Transit (PCAT™️) Module to Predict Intranasal Ketamine Pharmacokinetics in Pediatric Population

(W-016) Revumenib physiologically based pharmacokinetic model for evaluation of age effect and CYP3A4-mediated drug-drug interaction in relapsed/refractory acute leukemias

(W-021) Local TMDD of large molecules in tissue interstitial space

(W-024) Small molecule exposure prediction (intravenous (IV) and oral (PO)) using Machine learning (ML) in combination with mechanistic modeling.

(W-028) Development and application of physiologically based pharmacokinetic model of darunavir on pregnant population

(W-029) Physiologically based pharmacokinetic modelling to support the development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis: An MIDD case study

(W-038) Development of a Physiologically-Based Pharmacokinetic (PBPK) Model for Caffeine in Pregnancy: Evaluating Neonatal Transfer

(W-039) Predictive Pharmacokinetic Analysis of Novel PLCG2 Inhibitors Using GastroPlus and ADMET Predictor

(W-052) Hybrid Minimal Physiological-Based Pharmacokinetic Model of Tenofovir Alafenamide and Its Metabolites Disposition in Humans

(W-053) Development of physiologically based pharmacokinetic models for RET inhibitors to predict brain distribution

(W-066) PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF PIOGLITAZONE: EVALUATING THE EFFECT OF THE CYTOCHROME P450 2C8*2 SINGLE NUCLEOTIDE POLYMORPHISM

(W-087) Comparison of empirical and physiologically-based modeling approaches to explore mechanisms of drug-drug interaction between abemaciclib and olaparib in a small cohort of patients with ovarian cancer

(W-090) Physiologically Based Pharmacokinetic Model of Vedolizumab in Adult Patients with Inflammatory Bowel Disease

(W-095) Physiologically Based Pharmacokinetic (PBPK) modeling of hepatic impairment using PK-Sim

(W-104) Modeling Endothelial Cell-Targeted Polymeric Nanoparticle Delivery in Renal Glomeruli

(W-111) Pharmacokinetics of Long-Acting Naltrexone in Pregnancy: Insights from Physiologically Based Pharmacokinetic Modeling

(W-115) Leveraging PBPK modeling to advance spironolactone complex disposition knowledge

(W-119) Population pharmacokinetics of revumenib in patients with relapsed/refractory acute leukemias

(W-124) Real world examples of PBPK impact on CYP3A4 victim DDI drug label content

(W-129) Frailty phenotype as a sensitive indicator of aging-related Cytochrome P450 3A functional changes：Application of dose optimization recommendations for ticagrelor in the Chinese frail older population

(W-130) Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus® to Predict Hepatic Concentrations